OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
The tumour-necrosis-factor-family molecule osteoprotegerin ligand (OPGL; also known as TRANCE, RANKL and ODF) has been identified as a potential osteoclast differentiation factor and regulator of interactions between T cells and dendritic cells in vitro. Mice with a disrupted opgl gene show severe osteopetrosis and a defect in tooth eruption, and completely lack osteoclasts as a result of an inability of osteoblasts to support osteoclastogenesis. Although dendritic cells appear normal, opgl-deficient mice exhibit defects in early differentiation of T and B lymphocytes. Surprisingly, opgl-deficient mice lack all lymph nodes but have normal splenic structure and Peyer's patches. Thus OPGL is a new regulator of lymph-node organogenesis and lymphocyte development and is an essential osteoclast differentiation factor in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bone resorption is dependent on a cytokine known as RANKL (receptor activator of nuclear factor B ligand), a TNF family member that is essential for osteoclast formation, activity, and survival in normal and pathological states of bone remodeling.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [64]
In the citing paper
“In the absence of RANK or RANKL, osteoclasts cannot form, function, or survive (62-64, 110, 111).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [64]
In the citing paper
“RANK and RANKL knockout mice were virtual phenocopies of each other (62)(63)(64), which indicated that RANK and RANKL had few if any roles beyond their mutual interactions.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [64]
In the citing paper
“Another unexpected phenotype found in RANK and RANKL knockout mice was the total lack of lymph nodes (62,64).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [64]
In the citing paper
“Examination of mice genetically deficient in RANKL, RANK, or OPG also revealed no overt dendritic cell defects (62,64,170).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [64]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Self-citationOsteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Self-citationYasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228
Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara, S., Muramatsu, S., & Steinman, R. M. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.6.1693 · Cited by 3,738
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.
Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290
Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice
Soriano, P., Montgomery, C., Geske, R., & Bradley, A. (1991) · Cell · doi:10.1016/0092-8674(91)90499-o · Cited by 2,016
Yoshida, H., Hayashi, S.-I., Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., Sudo, T., Shultz, L. D., & Nishikawa, S.-I. (1990) · Nature · doi:10.1038/345442a0 · Cited by 1,789
Self-citationManolagas, S. C., & Jilka, R. L. (1995) · New England Journal of Medicine · doi:10.1056/nejm199502023320506 · Cited by 1,668
Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice.
Peschon, J. J., Morrissey, P. J., Grabstein, K. H., Ramsdell, F. J., Maraskovsky, E., Gliniak, B. C., Park, L. S., Ziegler, S. F., Williams, D. E., Ware, C. B., et al. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.5.1955 · Cited by 1,555
c-Fos: a Key Regulator of Osteoclast-Macrophage Lineage Determination and Bone Remodeling
Grigoriadis, A. E., Wang, Z.-Q., Cecchini, M. G., Hofstetter, W., Felix, R., Fleisch, H. A., & Wagner, E. F. (1994) · Science · doi:10.1126/science.7939685 · Cited by 1,260
Cited by
Items 501–600 of 1,030
Papadopoulos, G., Weinberg, E. O., Massari, P., Gibson, F. C., Wetzler, L. M., Morgan, E. F., & Genco, C. A. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202511 · Cited by 150
“Alveolar bone resorption is necessary for normal tooth eruption and root morphogenesis, both of which rely on intact receptor activator for NF-kB signaling (41).”
BackgroundPettit, A. R., Walsh, N. C., Manning, C., Goldring, S. R., & Gravallese, E. M. (2006) · Rheumatology · doi:10.1093/rheumatology/kel045 · Cited by 151
“RANKL is an essential factor for osteoclastogenesis both in vitro and in vivo [9, 10].”
BackgroundRANKL-induced M1 macrophages are involved in bone formation
Huang, R. S., Wang, X., Zhou, Y., & Xiao, Y. (2017) · Bone Research · doi:10.1038/boneres.2017.19 · Cited by 158
Balance of inflammatory response in stable gingivitis and progressive periodontitis lesions
Honda, T., Domon, H., Okui, T., Kajita, K., Amanuma, R., & Yamazaki, K. (2006) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2006.03028.x · Cited by 154
The role of immune responses in bone loss during periodontal disease
Baker, P. J. (2000) · Microbes and Infection · doi:10.1016/s1286-4579(00)01272-7 · Cited by 151
Takahashi, N., Udagawa, N., Takami, M., & Suda, T. (2002) · Elsevier eBooks · doi:10.1016/b978-012098652-1/50109-8 · Cited by 161
Juran, B. D., Hirschfield, G. M., Invernizzi, P., Atkinson, E. J., Li, Y., Xie, G., Kosoy, R., Ransom, M., Sun, Y., Bianchi, I., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds359 · Cited by 150
“Critical roles for RANKL in immunoregulation have been revealed by the absence of lymph nodes in RANKL-deficient mice (25) and by data showing RANKL involvement in the CD4+CD25+ regulatory T (Treg) cell development relevant Table 2.”
BackgroundDenosumab: an Emerging Therapy in Pediatric Bone Disorders
Boyce, A. M. (2017) · Current Osteoporosis Reports · doi:10.1007/s11914-017-0380-1 · Cited by 155
Jimi, E., Takakura, N., Hiura, F., Nakamura, I., & Hirata‐Tsuchiya, S. (2019) · Cells · doi:10.3390/cells8121636 · Cited by 160
“Mice that lack RANKL and its receptor RANK have severe osteopetrosis caused by a total lack of osteoclasts [18,19].”
BackgroundOkamoto, K., & Takayanagi, H. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031245 · Cited by 162
“AntiRANKL and anti-osteoclast therapies have 12 Cite this article as Cold Spring Harb Perspect Med 2019;9:a031245 w w w .p er sp ec ti ve si n m ed ic in e. o rg proved to be effective for treatment of bone loss in animal models of arthritis (Kong et al. 1999a; Takayanagi et al. 1999).”
InfluentialHwang, S.-J., Choi, B., Kang, S.-S., Chang, J.-H., Kim, Y.-G., Chung, Y.-H., Sohn, D. H., So, M. W., Lee, C.-K., Robinson, W. H., et al. (2012) · Arthritis Research & Therapy · doi:10.1186/ar3693 · Cited by 144
“Discussion Although RANKL is absolutely required for OC differentiation in vivo [28,29], several cytokines, including vascular endothelial growth factor and hepatocyte growth factor, can be substituted for M-CSF in promoting osteoclastogenesis [30-32].”
BackgroundRossi, F., Siniscalco, D., Luongo, L., PETROCELLIS, L. D., Bellini, G., Petrosino, S., Torella, M., Santoro, C., Nobili, B., Perrotta, S., et al. (2008) · Bone · doi:10.1016/j.bone.2008.10.056 · Cited by 155
Osteomacs and Bone Regeneration
Batoon, L., Millard, S. M., Raggatt, L. J., & Pettit, A. R. (2017) · Current Osteoporosis Reports · doi:10.1007/s11914-017-0384-x · Cited by 161
Differentiation and functions of osteoclasts and odontoclasts in mineralized tissue resorption
Sasaki, T. (2003) · Microscopy Research and Technique · doi:10.1002/jemt.10370 · Cited by 166
“RANKL-deficient mice showed a phenotype similar to severe osteopetrosis, in which osteoclastogenesis was completely inhibited (Dougall et al., 1999; Kong et al., 1999; Li et al., 2000).”
BackgroundKitazawa, S., Kajimoto, K., Kondo, T., & Kitazawa, R. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10567 · Cited by 147
“RANKL/ RANK interactions also regulate T-cell/dendritic cell communication [Anderson et al., 1997], dendritic cell survival [Anderson et al., 1997; Darnay et al., 1998], and lymph node formation [Kong et al., 1999].”
BackgroundYoshida, H., Kawamoto, H., Santee, S. M., Hashi, H., Honda, K., Nishikawa, S., Ware, C. F., Katsura, Y., & Nishikawa, S.-I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.5.2511 · Cited by 143
“However, there also appears to be a dichotomy in LN and PP formation, as PP can form in the absence of LN as in Osteoprotegerin ligand / (53), receptor activator of NF- B / (54), or TNFR-associated factor 6 / (55, 56) mice, and only PP is absent in the IL-7R / , Jak3 / , IL-2R / (2), and cpdm/cpdm mutant mice (57), im…”
BackgroundSelf-citationCapparelli, C., Kostenuik, P. J., Morony, S., Starnes, C. O., Weimann, B., Van, G. Y., Scully, S. A., Qi, M., Lacey, D. L., & Dunstan, C. R. (2000) · PubMed · Cited by 155
Self-citationOsteoblasts induce Ca 2+ oscillation-independent NFATc1 activation during osteoclastogenesis
Kuroda, Y., Hisatsune, C., Nakamura, T., Matsuo, K., & Mikoshiba, K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800642105 · Cited by 153
How we got attached to Actinobacillus actinomycetemcomitans: a model for infectious diseases
Fine, D. H., Kaplan, J. B., Kachlany, S. C., & Schreiner, H. C. (2006) · Periodontology 2000 · doi:10.1111/j.1600-0757.2006.00189.x · Cited by 184
Mizuno, A., Kanno, T., HOSHI, M., Shibata, O., Yano, K., Fujise, N., Kinosaki, M., Yamaguchi, K., Tsuda, E., Murakami, A., et al. (2002) · Journal of Bone and Mineral Metabolism · doi:10.1007/s007740200049 · Cited by 156
Lerner, U. H. (2004) · Critical Reviews in Oral Biology & Medicine · doi:10.1177/154411130401500202 · Cited by 177
Two populations of endochondral osteoblasts with differential sensitivity to Hedgehog signalling
Hammond, C. L., & Schulte-Merker, S. (2009) · Development · doi:10.1242/dev.042150 · Cited by 142
“Osteoclasts are of haematopoietic origin from the monocyte/ macrophage lineage, and their differentiation is controlled by RANKL (Tnfsf11 – Mouse Genome Informatics) and Csf1 (Kong et al., 1999; Yasuda et al., 1998).”
BackgroundKondo, H., Guo, J., & Bringhurst, F. R. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.9.1667 · Cited by 158
“In cells precultured for 7 days and then treated with PTH(1-34), similar reciprocal regulation of RANKL and OPG occurred, maximally at 6–24 h, that was of greater amplitude than the changes induced by chronic (7–10 days) PTH exposure.”
BackgroundInfluentialRegulation of bone resorption and formation by purines and pyrimidines
Hoebertz, A., Arnett, T. R., & Burnstock, G. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00123-8 · Cited by 147
Schulze, J., Bickert, T., Beil, F. T., Zaiss, M. M., Albers, J., Wintges, K., Streichert, T., Klaetschke, K., Keller, J., Hissnauer, T.-N., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.269 · Cited by 143
“This includes the cytokine receptor activator of NF-kB ligand (RANKL), the major positive regulator of osteoclastogenesis, which is produced not only by osteoblasts but also by activated T cells.((7)) Based on these observations, the interactions between bone and immune cells have been considered to be of critical imp…”
BackgroundHanada, R., Hanada, T., Sigl, V., Schramek, D., & Penninger, J. M. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0749-z · Cited by 154
“Most likely, loss of RANKL/RANK affects formation of the lymph node anlage and it might affect the function of lymph node inducer cells [10, 45].”
BackgroundInfluentialSelf-citationThe role of RANK ligand/osteoprotegerin in rheumatoid arthritis
Geusens, P. (2012) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x12438080 · Cited by 153
“…azM, P. Debyelaan 25, Postbus 5800, 6202 AZ Maastricht, The Netherlands piet.geusens@scarlet.be 226 http://tab.sagepub.com [Anderson et al. 1997; Kong et al. 1999] and was subsequently identified as soluble osteoclast activating factor produced by osteoblasts [Fuller et al. 1998; Lacey et al.…”
Estrogen deficiency, T cells and bone loss
Pacifici, R. (2008) · Cellular Immunology · doi:10.1016/j.cellimm.2007.06.008 · Cited by 146
Soluble RANKL and risk of nontraumatic fracture.
Schett, G. (2004) · JAMA · doi:10.1001/jama.291.9.1108 · Cited by 146
The Role of Macrophage in the Pathogenesis of Osteoporosis
Yang, D.-H., & Yang, M.-Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092093 · Cited by 128
“Mice with depletion of RANKL gene show severe osteopetrosis and lack mature circulating osteoclasts [40].”
BackgroundStepwise cell fate decision pathways during osteoclastogenesis at single-cell resolution
Tsukasaki, M., Huynh, N. C., Okamoto, K., Muro, R., Terashima, A., Kurikawa, Y., Komatsu, N., Pluemsakunthai, W., Nitta, T., Abe, T., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-00318-y · Cited by 148
Self-citationIida‐Klein, A., Zhou, H., Lu, S. S., Levine, L. R., Ducayen, M. B., Dempster, D. W., Nieves, J. W., & Lindsay, R. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.5.808 · Cited by 146
“have reported that human PTH(1-84) rescues the ovariectomy-induced bone loss in mice((13)) assessed by peripheral quantitative computed tomography (pQCT).”
BackgroundMethodInfluentialSecchiero, P., Corallini, F., Pandolfi, A., Consoli, A., Candido, R., Fabris, B., Celeghini, C., Capitani, S., & Zauli, G. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.060398 · Cited by 160
“Although the affinity of RANKL for OPG is weaker than that for RANK,(5) when present at high concentrations soluble OPG prevents RANKL interaction with transmembrane RANK, thus acting as a decoy receptor.(3,5) It has been shown that OPG is produced by a wide range of tissues, including the cardiovascular system, and t…”
BackgroundColucci, S., Brunetti, G., Rizzi, R., Zonno, A., Mori, G., Colaianni, G., Del Prete, D., Faccio, R., Liso, A., Capalbo, S., et al. (2004) · Blood · doi:10.1182/blood-2004-02-0474 · Cited by 146
Parathyroid Hormone Temporal Effects on Bone Formation and Resorption
Kroll, M. H. (2000) · Bulletin of Mathematical Biology · doi:10.1006/bulm.1999.0146 · Cited by 145
T he R ole of A cquired I mmunity and P eriodontal D isease P rogression
Teng, Y.-T. A. (2003) · Critical Reviews in Oral Biology & Medicine · doi:10.1177/154411130301400402 · Cited by 146
“RANK-L and its receptor RANK signaling pathway are essential for T-cell/dendritic-cell interactions, dendritic cell survival, lymph node formation, and organogenesis (Anderson et al., 1997; Kong et al., 1999a).”
InfluentialNandakumar, K. S., Bäcklund, J., Vestberg, M., & Holmdahl, R. (2004) · Arthritis Research & Therapy · doi:10.1186/ar1217 · Cited by 145
“Similarly, there are several ways in which T cells might be regulatory in an effector state like this: for example, they might control bone destruction through interaction with the osteoprotegrin system [23] or through the regulation of cytokines such as IFN-β, tumour necrosis factor-α or IL-4 [24-26].”
BackgroundXiong, J., Cawley, K., Piemontese, M., Fujiwara, Y., Zhao, H., Goellner, J. J., & O’Brien, C. A. (2018) · Nature Communications · doi:10.1038/s41467-018-05244-y · Cited by 144
Managing bone metastases and reducing skeletal related events in prostate cancer
Gartrell, B. A., & Saad, F. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.70 · Cited by 158
Zou, W., Hakim, I., Tschoep, K., Endres, S., & Bar‐Shavit, Z. (2001) · Journal of Cellular Biochemistry · doi:10.1002/jcb.1202 · Cited by 142
“An important step forward was the identi®cation of a factor promoting osteoclast differentiation from its bone-marrow precursor in the absence of supportive cells [Jimi et al., 1996; Anderson et al., 1997; Lacey et al., 1998; Kong et al., 1999; Suda et al., 1999; Takahashi et al., 1999].”
BackgroundAlnaeeli, M., Penninger, J. M., & Teng, Y.-T. A. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.5.3314 · Cited by 142
“To investigate whether the development of DDOC is RANKL dependent, OPG, anti-RANK Ab, or isotype control was added into the cocultures (11, 17).”
MethodSelf-citationDecreased Bone Turnover and Deterioration of Bone Structure in Two Cases of Pycnodysostosis
Fratzl‐Zelman, N., Valenta, A., Roschger, P., Nader, A., Gelb, B. D., Fratzl, P., & Klaushofer, K. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031055 · Cited by 144
Crockett, J. C., Mellis, D. J., Scott, D. I., & Helfrich, M. H. (2011) · Osteoporosis International · doi:10.1007/s00198-010-1272-8 · Cited by 143
“In mice, deletion of the genes for RANK or RANKL leads to profound osteopetrosis [3, 6, 64], whereas deletion of the gene for OPG leads to a high bone turnover osteoporosis [65].”
BackgroundStructural and Functional Insights of RANKL–RANK Interaction and Signaling
Liu, C., Walter, T. S., Huang, P., Zhang, S., Zhu, X., Wu, Y., Wedderburn, L. R., Tang, P., Owens, R. J., Stuart, D. I., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0904033 · Cited by 136
“Mice with a genetic mutation of rank, phenotypically exactly like rankl knock-out mice (24), have severely defective osteoclast development (25), which can be restored by the reintroduction of rank cDNA into bone marrow progenitor cells (26).”
BackgroundDuplomb, L., Baud’huin, M., Charrier, C., Berreur, M., Trichet, V., Blanchard, F., & Heymann, D. (2008) · Endocrinology · doi:10.1210/en.2007-1719 · Cited by 140
Childs, L. M., Paschalis, E. P., Xing, L., Dougall, W. C., Anderson, D., Boskey, A. L., Puzas, J. E., Rosier, R. N., O'Keefe, R. J., Boyce, B. F., et al. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.2.192 · Cited by 146
“Although these results were somewhat predicted from the knockout mouse studies, other published studies have concluded that osteoclastogenesis and osteoclastic bone resorption can occur independent of RANK signaling and that the absence of RANKL can be compensated for by tumor necrosis factor (TNF).”
BackgroundInfluentialSecreted Frizzled-Related Protein-1 Inhibits RANKL-Dependent Osteoclast Formation
Häusler, K. D., Horwood, N. J., Chuman, Y., Fisher, J. L., Ellis, J., Martin, T. J., Rubin, J. S., & Gillespie, M. T. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040807 · Cited by 142
“play severe osteopetrosis because of a complete lack of osteoclasts, whereas OPG / mice are osteoporotic because of an excess of osteoclasts.((5,6)) In addition, an absence of”
BackgroundRole of periodontal ligament fibroblasts in osteoclastogenesis: a review
Sokos, D., Everts, V. E., & de Vries, T. J. (2014) · Journal of Periodontal Research · doi:10.1111/jre.12197 · Cited by 160
Regulators of Osteoclast Differentiation and Cell-Cell Fusion
Miyamoto, T. K. (2011) · The Keio Journal of Medicine · doi:10.2302/kjm.60.101 · Cited by 163
Dr. Quinn, J. M. W., Horwood, N. J., Elliott, J., Gillespie, M. T., & Martin, T. J. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.8.1459 · Cited by 141
The Role of Osteocytes in Age-Related Bone Loss
Jilka, R. L., & O’Brien, C. A. (2016) · Current Osteoporosis Reports · doi:10.1007/s11914-016-0297-0 · Cited by 145
Kim, H. J., Chang, E., Kim, H., Lee, S. B., Kim, H.-D., Kim, G. S., & Kim, H. (2005) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2005.10.066 · Cited by 148
“However, the tumor necrosis factor (TNF) family cytokine RANKL (receptor activator of nuclear factor-κB ligand) and its receptor RANK are the fundamental components required for osteoclast differentiation [1–4].”
BackgroundKostenuik, P. J., Capparelli, C., Morony, S., Adamu, S., Shimamoto, G., Shen, V., Lacey, D. L., & Dunstan, C. R. (2001) · Endocrinology · doi:10.1210/endo.142.10.8437 · Cited by 140
Self-citationOdero‐Marah, V., Wang, R., Chu, G. C., Zayzafoon, M., Xu, J., Shi, C., Marshall, F. F., Zhau, H. E., & Chung, L. W. K. (2008) · Cell Research · doi:10.1038/cr.2008.84 · Cited by 155
Takegahara, N., Kim, H., & Choi, Y. (2022) · Bone · doi:10.1016/j.bone.2022.116353 · Cited by 143
Nguyen, L. T., Duncan, G. S., Mirtsos, C., Ng, M. S. W., Speiser, D. E., Shahinian, A., Marino, M. W., Mak, T. W., Ohashi, P. S., & Yeh, W. (1999) · Immunity · doi:10.1016/s1074-7613(00)80113-2 · Cited by 152
Self-citationDai, S.-M., Nishioka, K., & Yudoh, K. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.018481 · Cited by 152
Cells of the synovium in rheumatoid arthritis. Chondrocytes
Otero, M., & Goldring, M. B. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2292 · Cited by 154
Wang, C., Steer, J. H., Joyce, D. A., Yip, K. H. M., Zheng, M., & Xu, J. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.12.2159 · Cited by 145
“cDNA-Jun-(1-135) was expressed as glutathione S-transferase (GST) fusion proteins and purified by glutathione-Sepharose chromatography for use as substrates for JNK assays.”
BackgroundMethodClinical development of anti-RANKL therapy
Schwarz, E. M., & Ritchlin, C. T. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2171 · Cited by 145
“[24] and RANKL [25] knockout mice have altered”
BackgroundSrc Family Kinases as Therapeutic Targets in Advanced Solid Tumors: What We Have Learned So Far
Martellucci, S., Clementi, L., Sabetta, S., Mattei, V., Botta, L., & Angelucci, A. (2020) · Cancers · doi:10.3390/cancers12061448 · Cited by 139
“Drugs able to target Src were predicted in vitro to have a significant inhibitory effect on osteoclast activity [113].”
Feng, W., Li, W., Liu, W., Wang, F., Li, Y., & Yan, W. (2009) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2009.06.001 · Cited by 139
Dempster, D. W., Lambing, C. L., Kostenuik, P. J., & Grauer, A. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.02.002 · Cited by 146
“The first RANKL inhibitor tested in humans was recombinant OPG.”
BackgroundInfluentialIL-34 and CSF-1: similarities and differences
Nakamichi, Y., Udagawa, N., & Takahashi, N. (2013) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-013-0476-3 · Cited by 146
“CSF-1-mutated CSF-1 mice as well as RANKL-deficient (RANKL) mice exhibit osteopetrosis caused by osteoclast deficiency [23, 24, 60].”
BackgroundPathogenesis of arthritis: recent research progress
Feldmann, M. (2001) · Nature Immunology · doi:10.1038/ni0901-771 · Cited by 154
Kacena, M. A., Shivdasani, R. A., Wilson, K., Xi, Y., Troiano, N., Nazarian, A., Gundberg, C. M., Bouxsein, M. L., Lorenzo, J. A., & Horowitz, M. C. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301254 · Cited by 136
“blocked by addition of the decoy receptor osteoprotegerin.((4,5)) These results suggest that other hematopoietic”
BackgroundThe pathophysiology of cancer-induced bone pain: current understanding
Urch, C. (2004) · Palliative Medicine · doi:10.1191/0269216304pm887ra · Cited by 144
Polek, T. C., Talpaz, M., Darnay, B. G., & Spivak-Kroizman, T. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302518200 · Cited by 139
Essential Role for ADAM19 in Cardiovascular Morphogenesis
Zhou, H.-M., Weskamp, G., Chesneau, V., Sahin, U., Vortkamp, A., Horiuchi, K., Chiusaroli, R., Hahn, R., Wilkes, D., Fisher, P., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.1.96-104.2004 · Cited by 139
“Furthermore, overexpression of ADAM19 increases ectodomain release of tumor necrosis factor-related activation-induced cytokine (TRANCE, also referred to as osteoprotegerin-ligand [OPGL]) (7), a protein with important roles in osteoclast differentiation, dendritic cell survival, and mammary gland development (12, 25,…”
BackgroundRauner, M., Sipos, W., & Pietschmann, P. (2007) · International Archives of Allergy and Immunology · doi:10.1159/000098223 · Cited by 132
The many ways of osteoclast activation
Lorenzo, J. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94606 · Cited by 142
“RANKL is necessary for osteoclast formation and function, as mice lacking RANKL or its cognate cell-surface receptor, RANK, fail to form osteoclasts or resorb bone under homeostatic conditions (3, 4).”
Medication‐related dental implant failure: Systematic review and meta‐analysis
Chappuis, V., Avila‐Ortiz, G., Araújo, M. G., & Monje, A. (2018) · Clinical Oral Implants Research · doi:10.1111/clr.13137 · Cited by 126
Koshihara, Y., Hoshi, K., Okawara, R., Ishibashi, H., & Yamamoto, S. (2003) · Journal of Endocrinology · doi:10.1677/joe.0.1760339 · Cited by 160
“…mechanism underlying the ability of stromal cells/osteoblasts to support osteoclast formation was recently clarified by the identification of RANKL, a transmembrane protein that has proved to be an essential molecule for osteoclastogenesis (Lacey et al. 1998, Yasuda et al. 1998, Kong et al. 1999).”
BackgroundLee, C., Lee, E. Y., Chung, S. M., Mun, S. H., Yoo, B., & Moon, H. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20637 · Cited by 137
Bangert, C., Brunner, P. M., & Stingl, G. (2011) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2011.01.006 · Cited by 170
Chen, L., Wei, X., Evans, B. A. J., Jiang, W. G., & Aeschlimann, D. P. (2008) · European Journal of Immunology · doi:10.1002/eji.200838192 · Cited by 147
Atkins, G. J., Kostakis, P., Vincent, C., Farrugia, A. N., Houchins, J. P., Findlay, D. M., Evdokiou, A., & Zannettino, A. C. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060604 · Cited by 131
“Genetically modified mice deficient for RANK or its sole ligand, RANKL,((2)) have an almost complete lack of OCs, and as a consequence, are severely osteopetrotic.((3,39)) During osteoclastogenesis in the mouse, the acquisition of RANK was shown to follow that of c-Fms and to occur after stimulation with M-CSF.”
BackgroundRole of periodontal pathogenic bacteria in RANKL-mediated bone destruction in periodontal disease
Kajiya, M., Giro, G., Taubman, M. A., Han, X., Mayer, M. P. A., & Kawai, T. (2010) · Journal of Oral Microbiology · doi:10.3402/jom.v2i0.5532 · Cited by 149
“Gene knockout mice deficient in RANKL or RANK, respectively, not only present osteopetrotic phenotypes, but also lack peripheral lymph nodes (20, 55), supporting the idea that both RANKL and RANK play pivotal roles in osteoclastogenesis, as well as in the immune development, Mikihito Kajiya et al.”
BackgroundRANKL Employs Distinct Binding Modes to Engage RANK and the Osteoprotegerin Decoy Receptor
Nelson, C. A., Warren, J. T., Wang, M. W.-H., Teitelbaum, S. L., & Fremont, D. H. (2012) · Structure · doi:10.1016/j.str.2012.08.030 · Cited by 132
Cappariello, A., Loftus, A. E. P., Muraca, M., Maurizi, A., Rucci, N., & Teti, A. M. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3332 · Cited by 139
“One of the most paradigmatic molecules implicated in the osteoblast-osteoclast crosstalk is the receptor activator of nuclear factor k-B ligand (Rankl).((25)) Rankl is predominantly a transmembrane protein, also occasionally cleaved into a soluble form, which in bone is expressed by osteoblasts and osteocytes and whic…”
BackgroundMorgan, T., Atkins, G. J., Trivett, M. K., Johnson, S. A. S., Kansara, M., Schlicht, S., Slavin, J., Simmons, P. J., Dickinson, I. C., Powell, G., et al. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62959-8 · Cited by 136
“Lymphotoxin- receptor binds and transduces signals from tumor necrosis factor family proteins, to which RANKL and OPG belong.(31,32) Thrombospondin-1 has been reported to stimulate bone resorption by osteoclasts in vitro(33), whereas there have been two studies indicating that TYRO3 and its ligand, GAS6, stimulate ost…”
BackgroundSchneider, P., Olson, D. L., Tardivel, A., Browning, B., Lugovskoy, A. A., Gong, D., Dobles, M., Hertig, S., Hofmann, K., van Vlijmen, H., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210783200 · Cited by 155
Lu, H. ‐., Chen, Y. ‐., Chang, H. ‐., Li, C. ‐., & Kuo, M. Y. ‐. (2006) · Journal of Periodontal Research · doi:10.1111/j.1600-0765.2006.00883.x · Cited by 136
Osteoclasts and odontoclasts: signaling pathways to development and disease
Wang, Z., & McCauley, L. K. (2011) · Oral Diseases · doi:10.1111/j.1601-0825.2010.01718.x · Cited by 149
“RANKL mutant mice lack tooth eruption and also have defects in lymph node development (Kong et al, 1999b).”
BackgroundWatts, N. B., Roux, C., Modlin, J. F., Brown, J. P., Daniels, A., Jackson, S., Smith, S., Zack, D. J., Zhou, L., Grauer, A., et al. (2012) · Osteoporosis International · doi:10.1007/s00198-011-1755-2 · Cited by 135
“Gene deletion studies in rodents show that complete absence of RANKL or its receptor RANK during embryogenesis leads to absence of lymph nodes and changes in thymus architecture [3, 14].”
An, J., Hao, D., Zhang, Q., Chen, B., Zhang, R., Wang, Y., & Yang, H. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.04.024 · Cited by 138
Lee, C. A., & Einhorn, T. A. (2001) · Elsevier eBooks · doi:10.1016/b978-012470862-4/50002-7 · Cited by 143
Which elements are involved in reversible and irreversible cartilage degradation in osteoarthritis?
Bay‐Jensen, A., Madsen, S. H., Dam, E. B., Henriksen, K., Sondergaard, B. C., Pastoureau, P., Qvist, P., & Karsdal, M. A. (2009) · Rheumatology International · doi:10.1007/s00296-009-1183-1 · Cited by 145
“For example, RANK, the receptor for RANKL, has been identified on chondrocytes [13].”
BackgroundAoki, K., Saito, H., Itzstein, C., Ishiguro, M., Shibata, T., Blanque, R., Mian, A. H., Takahashi, M., Suzuki, Y., Yoshimatsu, M., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci22513 · Cited by 136
Sims, N. A., & Vrahnas, C. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.05.015 · Cited by 153
Büettner, M., & Lochner, M. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00342 · Cited by 149
“In contrast to LN development, however, both IL-7 and RANKL seem not to be pivotal for the development of PP, as PP primordia were detectable in IL-7−/− mice at E18 (31) and small PP develop in RANKL−/− mice (32).”
BackgroundRANKL and osteoimmunology in periodontitis
Tsukasaki, M. (2020) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-020-01165-3 · Cited by 142
Mozar, A., Haren, N., Chasseraud, M., Louvet, L., Mazière, C., Wattel, A., Mentaverri, R., Morlière, P., Kamel, S., Brazier, M., et al. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21283 · Cited by 144
“…necrosis factor (TNF) family member, called the receptor activator of nuclear factor kappa B ligand (RANKL) and its receptor (RANK), have been shown to control osteoclast differentiation, activation, and survival (Lacey et al., 1998; Burgess et al., 1999; Kong et al., 1999; Lacey et al., 2000).”
BackgroundRegulatory roles and molecular signaling of TNF family members in osteoclasts
Feng, X. (2005) · Gene · doi:10.1016/j.gene.2005.01.014 · Cited by 152
Molecular and functional characteristics of heart-valve interstitial cells
Chester, A. H., & Taylor, P. M. (2007) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2007.2126 · Cited by 148
Glucocorticoid-Induced Osteoporosis: Summary of a Workshop
Canalis, E., & Giustina, A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.12.8066 · Cited by 126
“It is likely that T cell-derived cytokines, particularly RANK-L, play a role in the bone loss of experimental arthritis and human rheumatoid arthritis (37, 38).”
BackgroundKim, Y.-M., Kim, Y.-M., Lee, Y. M., Kim, H.-S., Kim, J. D., Choi, Y., Kim, K.-W., Lee, S.-Y., & Kwon, Y.-G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109434200 · Cited by 125
Calcium signaling in osteoclasts
Hwang, S., & Putney, J. W. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2010.11.002 · Cited by 146
Characterization of osteoclast precursors in human blood
Shalhoub, V., Elliott, G., Chiu, L., Manoukian, R., Kelley, M., Hawkins, N., Davy, E., Shimamoto, G., Beck, J., Kaufman, S. A., et al. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02379.x · Cited by 131
Self-citationSerum osteoprotegerin levels in healthy controls and cancer patients.
Lipton, A., Ali, S. M., Leitzel, K., Chinchilli, V. M., Witters, L. M., Engle, L. L., Holloway, D. L., Bekker, P. J., & Dunstan, C. R. (2002) · PubMed · Cited by 145
Self-citation
Metadata
- Authors
- Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., Khoo, W., Wakeham, A., Dunstan, C. R., Lacey, D. L., Mak, T. W., Boyle, W. J., & Penninger, J. M.
- Affiliations
- University of Toronto (CA)
- Amgen (United States) (US)
- Corresponding author
- Penninger, Josef M.
- Venue
- Nature
- Published
- 1999-01
- Volume
- 397
- Issue
- 6717
- Pages
- 315-323
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1534645474
- Cited by
- 3,351
- References
- 52
- Citations by year
- 2026: 27 · 2025: 47 · 2024: 58 · 2023: 71 · 2022: 88 · 2021: 114 · 2020: 121 · 2019: 102 · 2018: 95 · 2017: 115 · 2016: 107 · 2015: 125 · 2014: 119 · 2013: 138 · 2012: 162
- FWCI
- 49.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Keywords
- osteoprotegerin ligand, RANKL, osteoclastogenesis, osteopetrosis, tooth eruption, lymphocyte development, dendritic cells, T cell development, B cell development, osteoblasts
- MeSH terms
- Animals, B-Lymphocytes, Carrier Proteins, Cell Differentiation, Cells, Cultured, Dendritic Cells, Female, Embryonic and Fetal Development, Growth Substances, Hematopoiesis, Extramedullary, Hematopoietic Stem Cells, Lymph Nodes, Lymphocyte Activation, Lymphocytes, Male, Membrane Glycoproteins, Mice, Inbred BALB C, Mice, Inbred C57BL, Molecular Sequence Data, Osteoclasts, Osteogenesis, Osteopetrosis, T-Lymphocytes, Thymus Gland, Cytokines, Mutagenesis, Bone Remodeling, Gene Targeting, Leukopoiesis, Mice, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.